Advertisement

Systematic review of the diagnostic utility of SPECT imaging in dementia

  • Jing Ming Yeo
  • Xuxin Lim
  • Zubair Khan
  • Suvankar Pal
Invited Review

Abstract

Single-photon emission-computed tomography (SPECT) may potentially contribute to the diagnostic work up of patients with neurodegenerative dementia. This systematic review aims to establish the diagnostic utility of 99mTc-hexamethylpropyleneamine (99mTc-HMPAO) and 99mTc-ethylcysteine dimer SPECT in distinguishing between Alzheimer’s disease (AD) and frontotemporal dementia (FTD), AD and vascular dementia (VD), AD and dementia with Lewy bodies (DLB), and AD and normal controls (NC). We searched MEDLINE and Embase databases via OVID for articles from January 1985 to May 2012 and identified additional studies from reviews and references. Of 755 studies, 49 studies met the inclusion and exclusion criteria for this systematic review; AD versus FTD (n = 13), AD versus VD (n = 18), AD versus DLB (n = 5), and AD versus NC (n = 18). We compiled relevant data and graded the studies with an internal and external validity criteria checklist. We pooled the studies with a clinical diagnosis and those using 99mTc-HMPAO SPECT in a meta-analysis, calculating the pooled weighted sensitivity, specificity, likelihood ratios, and diagnostic odds ratios using DerSimonian–Laird random-effects model. The pooled weighted sensitivity and specificity of 99mTc-HMPAO-SPECT in distinguishing clinically diagnosed AD from FTD are 79.7 and 79.9 %, respectively, AD from VD are 74.5 and 72.4 %, AD from DLB are 70.2 and 76.2 %, and AD from NC are 76.1 and 85.4 %. SPECT does have diagnostic value, particularly in differentiating Alzheimer’s disease from frontotemporal dementia and normal controls; however, it should not be used in isolation, rather as an adjunct, and interpreted in the context of clinical information and paraclinical test results.

Keywords

Dementia Imaging SPECT Alzheimer’s disease Frontotemporal dementia 

Notes

Acknowledgments

Dr Suvankar Pal is funded by a fellowship from NHS Research Scotland.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Pimlott SL, Ebmeier KP (2007) SPECT imaging in dementia. Br J Radiol 80 Spec No 2:S153–S159Google Scholar
  2. 2.
    Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P, EFNS Scientist Panel on Dementia (2010) EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 17(10):1236–1248Google Scholar
  3. 3.
    Fairbairn A, Gould N, Kendall T, Ashley P, Bainbridge I, Bower L et al (2006) Dementia—supporting people with dementia and their carers in health and social care (NICE Guideline 42). National Institute for Health and Clinical Excellence, LondonGoogle Scholar
  4. 4.
    Dougall NJ, Bruggink S, Ebmeier KP (2004) Systemic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 12:554–570PubMedGoogle Scholar
  5. 5.
    Tartaglia MC, Rosen HJ, Miller BL (2011) Neuroimaging in dementia. Neurotherapeutics 8(1):82–92PubMedCrossRefGoogle Scholar
  6. 6.
    Lefebvre C, Clarke MJ (2001) Identifying randomised trials. In: Egger M, Smith GD, Altman DG (eds) Systematic reviews in health care: meta-analysis in context, 2nd edn. BMJ, London, pp 69–86CrossRefGoogle Scholar
  7. 7.
    Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, De Vet HCW (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Radiol 58:575–580PubMedCrossRefGoogle Scholar
  8. 8.
    Scottish Intercollegiate Guidelines Network (SIGN) Methodology Checklist 5: Studies of Diagnostic Accuracy (2006). Edinburgh Scottish Intercollegiate Guidelines NetworkGoogle Scholar
  9. 9.
    StatsDirect Ltd (2008) StatsDirect statistical software. StatsDirect Ltd. http://www.statsdirect.com. Accessed 15th June 2012
  10. 10.
    Zamora J, Abraira V, Muriel A, Khan KS, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31PubMedCrossRefGoogle Scholar
  11. 11.
    Irwig L, Macaskill P, Glasziou P, Fahey M (1995) Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 48(1):119–130PubMedCrossRefGoogle Scholar
  12. 12.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558PubMedCrossRefGoogle Scholar
  13. 13.
    Boutoleau-Bretonnière C, Lebouvier T, Delaroche O, Lamy E, Evrard C, Charriau T, Bretonnière C, Damier P, Derkinderen P, Vercelletto M (2012) Value of neuropsychological testing, imaging, and CSF biomarkers for the differential diagnosis and prognosis of clinically ambiguous dementia. J Alzheimers Dis 28(2):323–336PubMedGoogle Scholar
  14. 14.
    Charpentier P, Lavenu I, Defebvre L, Duhamel A, Lecouffe P, Pasquier F, Steinling M (2000) Alzheimer’s disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data. J Neurol Neurosurg Psychiatry 69(5):661–663PubMedCrossRefGoogle Scholar
  15. 15.
    Doran M, Vinjamuri S, Collins J, Parker D, Larner AJ (2005) Single-photon emission computed tomography perfusion imaging in the differential diagnosis of dementia: a retrospective regional audit. Int J Clin Pract 59(4):496–500PubMedCrossRefGoogle Scholar
  16. 16.
    Kaneko K, Kuwabara Y, Sasaki M, Ogomori K, Ichimiya A, Koga H, Nakagawa M, Hayashi K, Honda H (2004) Posterior cingulate hypoperfusion in Alzheimer’s disease, senile dementia of Alzheimer type, and other dementias evaluated by three-dimensional stereotactic surface projections using Tc-99m HMPAO SPECT. Clin Nucl Med 29(6):362–366PubMedCrossRefGoogle Scholar
  17. 17.
    McNeill R, Sare GM, Manoharan M, Testa HJ, Mann DM, Neary D, Snowden JS, Varma AR (2007) Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer’s disease. J Neurol Neurosurg Psychiatry 78(4):350–355PubMedCrossRefGoogle Scholar
  18. 18.
    Nagao M, Sugawara Y, Ikeda M, Fukuhara R, Hokoishi K, Murase K, Mochizuki T, Miki H, Kikuchi T (2004) Heterogeneity of cerebral blood flow in frontotemporal lobar degeneration and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 31(2):162–168Google Scholar
  19. 19.
    Pasquier F, Lavenu I, Lebert F, Jacob B, Steinling M, Petit H (1997) The use of SPECT in a multidisciplinary memory clinic. Dement Geriatr Cogn Disord 8(2):85–91PubMedCrossRefGoogle Scholar
  20. 20.
    Pickut BA, Saerens J, Mariën P, Borggreve F, Goeman J, Vandevivere J, Vervaet A, Dierckx R, de Deyn PP (1997) Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer’s type. J Nucl Med 38(6):929–934PubMedGoogle Scholar
  21. 21.
    Sjögren M, Gustafson L, Wikkelsö C, Wallin A (2000) Frontotemporal dementia can be distinguished from Alzheimer’s disease and subcortical white matter dementia by an anterior-to-posterior rCBF-SPET ratio. Dement Geriatr Cogn Disord 11(5):275–285PubMedCrossRefGoogle Scholar
  22. 22.
    Testa HJ, Snowden JS, Neary D, Shields RA, Burjan AW, Prescott MC, Northen B, Goulding P (1988) The use of [99mTc]-HM-PAO in the diagnosis of primary degenerative dementia. J Cereb Blood Flow Metab 8(6):S123–S126PubMedCrossRefGoogle Scholar
  23. 23.
    Tripathi M, Tripathi M, Vibha D, Gowda N, Bal C, Malhotra A (2010) Tc-99m ethylcysteinate dimer SPECT in the differential diagnosis of dementias. Neurol India 58(6):857–862PubMedCrossRefGoogle Scholar
  24. 24.
    Varma AR, Adams W, Lloyd JJ, Carson KJ, Snowden JS, Testa HJ, Jackson A, Neary D (2002) Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer’s disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 105(4):261–269PubMedCrossRefGoogle Scholar
  25. 25.
    Velakoulis D, Lloyd JH (1998) The role of SPECT scanning in a neuropsychiatry unit. Aust N Z J Psychiatry 32(4):511–522PubMedCrossRefGoogle Scholar
  26. 26.
    Battistin L, Pizzolato G, Dam M, Ponza I, Borsato N, Zanco PL, Ferlin G (1990) Regional cerebral blood flow study with 99mTc-hexamethyl-propyleneamine oxime single photon emission computed tomography in Alzheimer’s and multi-infarct dementia. Eur Neurol 30(5):296–301PubMedCrossRefGoogle Scholar
  27. 27.
    Bergman H, Chertkow H, Wolfson C, Stern J, Rush C, Whitehead V, Dixon R (1997) HM-PAO (CERETEC) SPECT brain scanning in the diagnosis of Alzheimer’s disease. J Am Geriatr Soc 45(1):15–20PubMedGoogle Scholar
  28. 28.
    Butler RE, Costa DC, Greco A, Ell PJ, Katona CLE (1995) Differentiation between Alzheimer’s disease and multi-infarct dementia: SPECT vs MR imaging. Int J Geriatr Psychiatry 10(2):121–128CrossRefGoogle Scholar
  29. 29.
    deFigueiredo RG, Shankle WR, Maccato A, Dick MB, Mundkur P, Mena I, Cotman CW (1995) Neural-network-based classification of cognitively normal, demented, Alzheimer disease and vascular dementia from single photon emission with computed tomography image data from brain. Proc Natl Acad Sci USA 92(12):5530–5534PubMedCrossRefGoogle Scholar
  30. 30.
    Gemmell HG, Sharp PF, Besson JA, Crawford JR, Ebmeier KP, Davidson J, Smith FW (1987) Differential diagnosis in dementia using the cerebral blood flow agent 99mTc HM-PAO: a SPECT study. J Comput Assist Tomogr 11(3):398–402PubMedCrossRefGoogle Scholar
  31. 31.
    Gemmell HG, Sharp PF, Smith FW, Besson JA, Ebmeier KP, Davidson J, Evans NT, Roeda D, Newton R, Mallard JR (1989) Cerebral blood flow measured by SPECT as a diagnostic tool in the study of dementia. Psychiatry Res 29(3):327–329PubMedCrossRefGoogle Scholar
  32. 32.
    Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A (1992) The scintigraphic appearance of Alzheimer’s disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med 33(2):181–185PubMedGoogle Scholar
  33. 33.
    Ishii S, Shishido F, Miyajima M, Sakuma K, Shigihara T, Tameta T, Miyazaki M, Kuroda H (2009) Comparison of Alzheimer’s disease with vascular dementia and non-dementia using specific voxel-based Z score maps. Ann Nucl Med 23(1):25–31PubMedCrossRefGoogle Scholar
  34. 34.
    Jobst KA, Barnetson LP, Shepstone BJ (1998) Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 10(3):271–302PubMedCrossRefGoogle Scholar
  35. 35.
    Launes J, Sulkava R, Erkinjuntti T, Nikkinen P, Lindroth L, Liewendahl K, Iivanainen M (1991) 99Tcm-HMPAO SPECT in suspected dementia. Nucl Med Commun 12(9):757–765PubMedCrossRefGoogle Scholar
  36. 36.
    Lee BF, Liu CK, Tai CT, Chiu NT, Liu GC, Yu HS, Pai MC (2001) Alzheimer’s disease: scintigraphic appearance of Tc-99m HMPAO brain SPECT. Kaohsiung J Med Sci 17(8):394–400PubMedGoogle Scholar
  37. 37.
    Masterman DL, Mendez MF, Fairbanks LA, Cummings JL (1997) Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer’s disease from other dementias. J Geriatr Psychiatry Neurol 10(1):15–21PubMedGoogle Scholar
  38. 38.
    Pávics L, Grünwald F, Reichmann K, Horn R, Kitschenberg A, Hartmann A, Menzel C, Schomburg AG, Overbeck B, Csernay L, Biersack HJ (1999) Regional cerebral blood flow single-photon emission tomography with 99mTc-HMPAO and the acetazolamide test in the evaluation of vascular and Alzheimer’s dementia. Eur J Nucl Med 26(3):239–245PubMedCrossRefGoogle Scholar
  39. 39.
    Sloan EP, Fenton GW, Kennedy NS, MacLennan JM (1995) Electroencephalography and single photon emission computed tomography in dementia: a comparative study. Psychol Med 25(3):631–638PubMedCrossRefGoogle Scholar
  40. 40.
    Smith FW, Besson JA, Gemmell HG, Sharp PF (1988) The use of technetium-99m-HM-PAO in the assessment of patients with dementia and other neuropsychiatric conditions. J Cereb Blood Flow Metab 8(6):S116–S122PubMedCrossRefGoogle Scholar
  41. 41.
    Villa G, Cappa A, Tavolozza M, Gainotti G, Giordano A, Calcagni ML, De Rossi G (1995) Neuropsychological tests and [99mTc]-HM PAO SPECT in the diagnosis of Alzheimer’s dementia. J Neurol 242(6):359–366PubMedCrossRefGoogle Scholar
  42. 42.
    Colloby SJ, Taylor JP, Firbank MJ, McKeith IG, Williams ED, O’Brien JT (2010) Covariance 99mTc-exametazime SPECT patterns in Alzheimer’s disease and dementia with Lewy bodies: utility in differential diagnosis. J Geriatr Psychiatry Neurol 23(1):54–62PubMedCrossRefGoogle Scholar
  43. 43.
    Defebvre LJ, Leduc V, Duhamel A, Lecouffe P, Pasquier F, Lamy-Lhullier C, Steinling M, Destée A (1999) Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer’s disease and idiopathic Parkinson’s disease. J Nucl Med 40(6):956–962PubMedGoogle Scholar
  44. 44.
    Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, Poewe W, Ransmayr G (1997) Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 24(3):320–325PubMedGoogle Scholar
  45. 45.
    Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, McKeith IG, O’Brien JT (2001) Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56(5):643–649PubMedCrossRefGoogle Scholar
  46. 46.
    Pasquier J, Michel BF, Brenot-Rossi I, Hassan-Sebbag N, Sauvan R, Gastaut JL (2002) Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 29(10):1342–1348PubMedCrossRefGoogle Scholar
  47. 47.
    Claus JJ, van Harskamp F, Breteler MM, Krenning EP, de Koning I, van der Cammen TJ, Hofman A, Hasan D (1994) The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer’s disease: a population-based study. Neurology 44(3 Pt 1):454–461PubMedCrossRefGoogle Scholar
  48. 48.
    Colloby SJ, Firbank MJ, Pakrasi S, Lloyd JJ, Driver I, McKeith IG, Williams ED, O’Brien JT (2008) A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer’s disease and dementia with Lewy bodies. Int Psychogeriatr 20(6):1124–1140PubMedCrossRefGoogle Scholar
  49. 49.
    Elgh E, Sundström T, Näsman B, Ahlström R, Nyberg L (2002) Memory functions and rCBF (99m)Tc-HMPAO SPET: developing diagnostics in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 29(9):1140–1148PubMedCrossRefGoogle Scholar
  50. 50.
    Fleming JS, Kemp PM, Bolt L, Goatman KA (2002) Measurement of cerebral perfusion volume and 99mTc-HMPAO uptake using SPECT in controls and patients with Alzheimer’s disease. Nucl Med Commun 23(11):1057–1064PubMedCrossRefGoogle Scholar
  51. 51.
    Greene JD, Miles K, Hodges JR (1996) Neuropsychology of memory and SPECT in the diagnosis and staging of dementia of Alzheimer type. J Neurol 243(2):175–190PubMedCrossRefGoogle Scholar
  52. 52.
    Hurwitz TA, Ammann W, Chu D, Clark C, Holden J, Brownstone R (1991) Single photon emission computed tomography using 99mTc-HM-PAO in the routine evaluation of Alzheimer’s disease. Can J Neurol Sci 18(1):59–62PubMedGoogle Scholar
  53. 53.
    Jagust W, Thisted R, Devous MD Sr, Van Heertum R, Mayberg H, Jobst K, Smith AD, Borys N (2001) SPECT perfusion imaging in the diagnosis of Alzheimer’s disease: a clinical-pathologic study. Neurology 56(7):950–956PubMedCrossRefGoogle Scholar
  54. 54.
    Johnson KA, Kijewski MF, Becker JA, Garada B, Satlin A, Holman BL (1993) Quantitative brain SPECT in Alzheimer’s disease and normal aging. J Nucl Med 34(11):2044–2048PubMedGoogle Scholar
  55. 55.
    Karbe H, Kertesz A, Davis J, Kemp BJ, Prato FS, Nicholson RL (1994) Quantification of functional deficit in Alzheimer’s disease using a computer-assisted mapping program for 99mTc-HMPAO SPECT. Neuroradiology 36(1):1–6PubMedCrossRefGoogle Scholar
  56. 56.
    Müller H, Möller HJ, Stippel A, Fric M, Grünwald F, Laux G, Klemm E, Biersack HJ (1999) SPECT patterns in probable Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 249(4):190–196PubMedCrossRefGoogle Scholar
  57. 57.
    O’Brien JT, Ames D, Desmond P, Lichtenstein M, Binns D, Schweitzer I, Davis S, Tress B (2001) Combined magnetic resonance imaging and single-photon emission tomography scanning in the discrimination of Alzheimer’s disease from age-matched controls. Int Psychogeriatr 13(2):149–161PubMedCrossRefGoogle Scholar
  58. 58.
    O’Mahony D, Coffey J, Murphy J, O’Hare N, Hamilton D, Freyne P, Walsh JB, Coakley D (1994) The discriminant value of semiquantitative SPECT data in mild Alzheimer’s disease. J Nucl Med 35(9):1450–1455PubMedGoogle Scholar
  59. 59.
    Pagani M, Salmaso D, Rodriguez G, Nardo D, Nobili F (2009) Principal component analysis in mild and moderate Alzheimer’s disease–a novel approach to clinical diagnosis. Psychiatry Res 173(1):8–14PubMedCrossRefGoogle Scholar
  60. 60.
    Tsolaki M, Sakka V, Gerasimou G, Dimacopoulos N, Chatzizisi O, Fountoulakis KN, Kyriazis G, Papanastasiou J, Kazis A (2001) Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer’s type, other types of dementia, and control subjects. Am J Alzheimers Dis Other Demen 16(1):21–31PubMedCrossRefGoogle Scholar
  61. 61.
    Van Gool WA, Walstra GJ, Teunisse S, Van der Zant FM, Weinstein HC, Van Royen EA (1995) Diagnosing Alzheimer’s disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. J Neurol 242(6):401–405PubMedCrossRefGoogle Scholar
  62. 62.
    Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D (1999) Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 66(2):184–188PubMedCrossRefGoogle Scholar
  63. 63.
    Toghi H, Chiba K, Sasaki K, Hiroi S, Ishibashi Y (1991) Cerebral perfusion patterns in vascular dementia of Binswanger type compared with senile dementia of the Alzheimer type: a SPECT study. J Neurol 238:365–370CrossRefGoogle Scholar
  64. 64.
    Grégoire G, Derderian F, Le Lorier J (1995) Selecting the language of the publications included in a meta-analysis: is there a tower of Babel bias? J Clin Epidemiol 48(1):159–163PubMedCrossRefGoogle Scholar
  65. 65.
    Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE (2000) FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41(11):1920–1928PubMedGoogle Scholar
  66. 66.
    Bonte FJ, Weiner MF, Bigio EH, White CL 3rd (1997) Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 202(3):793–797PubMedGoogle Scholar
  67. 67.
    Poljansky S, Ibach B, Hirschberger B, Männer P, Klünemann H, Hajak G, Marienhagen J (2011) A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration. Eur Arch Psychiatry Clin Neurosci 261(6):433–446PubMedCrossRefGoogle Scholar
  68. 68.
    Ishii K, Hosaka K, Mori T, Mori E (2004) Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med 18(5):447–451PubMedCrossRefGoogle Scholar
  69. 69.
    Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O’Neil JP, Janabi M, Baker SL, Agarwal N, Bonasera SJ, Mormino EC, Weiner MW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ (2010) Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden. Brain 133(Pt 2):512–528PubMedCrossRefGoogle Scholar
  70. 70.
    Ebmeier KP (2010) Is there still a place for perfusion SPECT in the diagnosis of dementia? Open Nucl Med J 2:40–45CrossRefGoogle Scholar
  71. 71.
    Murray AD (2012) Imaging approaches for dementia. AJNR Am J Neuroradiol 33(10):1836–1844PubMedCrossRefGoogle Scholar
  72. 72.
    Davatzikos C, Resnick SM, Wu X, Parmpi P, Clark CM (2008) Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage 41(4):1220–1227PubMedCrossRefGoogle Scholar
  73. 73.
    Genius J, Klafki H, Benninghoff J, Esselmann H, Wiltfang J (2012) Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer’s disease and other neurodegenerative dementias. Eur Arch Psychiatry Clin Neurosci 262(Suppl 2):S71–S77PubMedCrossRefGoogle Scholar
  74. 74.
    Sonnen JA, Montine KS, Quinn JF, Breitner JCS, Montine TJ (2010) Cerebrospinal fluid biomarkers in mild cognitive impairment and Dementia. J Alzheimers Dis 19(1):301–309PubMedGoogle Scholar
  75. 75.
    Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56(9):1143–1153Google Scholar
  76. 76.
    Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52(8):1555–1562PubMedCrossRefGoogle Scholar
  77. 77.
    Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61(1):95–102PubMedCrossRefGoogle Scholar
  78. 78.
    Ceravolo R, Borghetti D, Kiferle L, Tognoni G, Giorgetti A, Neglia D, Sassi N, Frosini D, Rossi C, Petrozzi L, Siciliano G, Murri L (2008) CSF phosphorylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer’s disease. Brain Res Bull 76(1–2):80–84PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.College of Medicine and Veterinary MedicineUniversity of EdinburghEdinburghUK
  2. 2.Department of Nuclear Medicine and RadiologyNHS LothianEdinburghUK
  3. 3.Anne Rowling Regenerative Neurology ClinicUniversity of EdinburghEdinburghUK
  4. 4.Department of Clinical NeurosciencesWestern General HospitalEdinburghUK
  5. 5.Department of Clinical NeurologyForth Valley Royal HospitalLarbertUK

Personalised recommendations